Curium is reportedly in advanced discussions to acquire Lantheus Holdings Inc., a fellow radiopharma company. The potential deal could be finalized and announced within days, according to sources close to the negotiations. While specific financial terms have not been officially disclosed, preliminary reports suggest the acquisition could be valued at approximately $7 billion. This move would represent a significant consolidation within the radiopharmaceutical sector, potentially reshaping the competitive landscape.

Lantheus, known for its diagnostic imaging agents and radiopharmaceutical therapeutics, has been a key player in the industry. A combination with Curium, which also specializes in nuclear medicine, would create a larger entity with a broader portfolio and enhanced market reach. The timing of the announcement remains fluid, as is typical in such high-stakes negotiations, but the proximity to a resolution indicates a strong likelihood of the deal proceeding.

Further details regarding the structure of the acquisition and any potential regulatory hurdles are expected to emerge once a definitive agreement is reached. The implications for patients, healthcare providers, and shareholders will become clearer as more information becomes available. This potential transaction underscores the ongoing M&A activity in the life sciences sector, driven by the pursuit of innovation and market expansion.